Comparison of open and closed abdomen techniques for the delivery of intraperitoneal pemetrexed using a murine model

Badrudin, David; Sidéris, Lucas; Perrault-Mercier, Camille; Hubert, Julien; Leblond, François; Dubé, Pierre

doi:10.1002/jso.24960

Cited by 8 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While open vs. closed techniques have not been directly compared in humans, a murine model study in 2018 demonstrated some important potential differences. Eleven male rats received fixed-dose intraperitoneal pemetrexed at perfusion temperature of 40 ℃ for 25 minutes via open or closed techniques (39). Postoperative drug concentration in the portal blood, systemic blood and peritoneal tissue were measured.…”

Section: Surgical Approachesmentioning

confidence: 99%

Peritoneal mesothelioma

Greenbaum¹,

Alexander²

2020

Transl Lung Cancer Res

View full text Add to dashboard Cite

Malignant peritoneal mesothelioma (MPM) is a rare and lethal disease of the peritoneal lining, with high variability in biologic aggressiveness. Morbidity and mortality of the disease are related to progressive locoregional effects within the abdominal cavity, such as distention, pain, early satiety, and decreased oral intake that can ultimately lead to bowel obstruction and cachexia. The standard of care for patients with resectable disease remains cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), with potential survival outcomes greater than 5 years in appropriately selected patients. Patients with inoperable MPM can be offered systemic treatment, although the disease is usually refractory to standard chemotherapic regimens. Patients with MPM should be treated at high volume centers with strong consideration for inclusion in tumor registries and clinical trials. In 2020, research will continue to explore promising genetic and immunologic targets and focus on refinement of surgical methods to optimize CRS-HIPEC approaches.

show abstract

Section: Surgical Approachesmentioning

confidence: 99%

Peritoneal mesothelioma

Greenbaum¹,

Alexander²

2020

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

“…Bowel anastomoses were performed after the HIPEC until 2008, when anastomoses were performed before the HIPEC. The open approach for HIPEC [14, 20] was performed until 2011, when all HIPECs were performed using the closed approach [21, 22]. Details of our HIPEC procedure has been previously described [14]; however, in brief, patients receive a systemic dose of fluorouracil (5-FU) (400 mg/m 2 ) and leucovorin (20 mg/m 2 ) 1 hour prior to HIPEC.…”

Section: Methodsmentioning

confidence: 99%

Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background Peritoneal carcinomatosis (PC) from colorectal cancer is associated with poor prognosis. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has improved survival for patients with colorectal peritoneal carcinomatosis. However, standardization of HIPEC protocols, including which chemotherapeutic agent to use, is lacking in the literature. Therefore, we sought to report survival outcomes from colorectal cancer patients undergoing CRS/oxaliplatin-based HIPEC at our institution over the last 10 years. Methods Colorectal PC patients treated with CRS/oxaliplatin-based HIPEC 2004–2015 were included. Demographic, clinical, and oncologic data were abstracted from the medical record. Overall (OS) and disease-free survival (DFS) were calculated using Kaplan–Meier analysis. Univariate/multivariate Cox regression analysis was done. Results Laparotomy was performed in 113 patients for colorectal PC; 91 completed a curative intent CRS/HIPEC. At 3 and 5 years, OS for the CRS/HIPEC cohort was 75% and 55%, and DFS was 50% and 25%, respectively. On multivariate analysis, incremental increases in peritoneal carcinomatosis index (PCI) were associated with worse OS ( p = 0.0001) and DFS ( p = 0.0001). Grade III/IV complications were also associated with worse OS. Conclusions A standardized regimen of CRS and oxaliplatin-based HIPEC for colorectal PC is effective with favorable OS and DFS and acceptable complication rates.

show abstract

“…Depending on the origin of the used cancer cells, rat and mouse strains were chosen. The following rat types were used in the analyzed articles; Wistar (21%) [ 32 , 45 , 46 , 62 , 63 , 64 ], Sprague Dawley (32%) [ 40 , 43 , 51 , 52 , 57 , 65 , 66 , 67 , 68 ], WAG/Rij (32%) [ 47 , 54 , 69 , 70 , 71 , 72 , 73 , 74 , 75 ] and athymic/nude (14%) [ 44 , 76 , 77 , 78 ] rats. For mouse experiments, the following strains were used: Swiss albino (20%) [ 36 , 38 , 79 ], athymic (33%) [ 37 , 48 , 50 , 55 , 80 ], C57BL/6 (20%) [ 33 , 39 , 81 ], BALB/c (20%) [ 49 , 56 , 82 ] and NOD-SCID (7%) [ 34 ].…”

Section: Preclinical Hipec Modelsmentioning

confidence: 99%

“…The effect of the delivery technique on the temperature or drug distribution was not assessed. Badrudin et al treated eleven rats with pemetrexed for 25 min at 40 °C using either the open or closed delivery techniques [ 57 ]. Peritoneal tissue concentration showed no difference, but higher systemic concentrations were observed using the open delivery technique, suggesting it could increase systemic toxicity.…”

Section: Physiological and Anticancer Aspects Of Preclinical Hipec Modelsmentioning

confidence: 99%

Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges

Helderman

Löke

Tanis

et al. 2021

Cancers

View full text Add to dashboard Cite

Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for patients with peritoneal metastasis (PM) of various origins which aims for cure in combination with cytoreductive surgery (CRS). Efficacy of CRS-HIPEC depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assist in designing potentially more effective treatment protocols and clinical trials. The different methodologies for peritoneal disease and HIPEC are variable. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In this review, recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments.

show abstract

Comparison of open and closed abdomen techniques for the delivery of intraperitoneal pemetrexed using a murine model

Abstract: Peritoneal absorption of pemetrexed is not modified by the use of either technique. However, systemic concentrations of pemetrexed increased using the open technique, suggesting it could increase systemic toxicity.

Cited by 8 publications

References 23 publications

Peritoneal mesothelioma

Peritoneal mesothelioma

Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study

Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges

Contact Info

Product

Resources

About